Letrozole

• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting
  2023-505871-63-00 Phase III 13 countries Olema Pharmaceuticals Inc.
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 Phase III 16 countries AstraZeneca AB
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting
  2022-501453-36-00 Phase III 11 countries European Organisation For Research And Treatment Of Cancer
• IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-contr… Recruiting
  2023-506620-87-00 Phase III/IV 6 countries Region Oerebro Laen
• Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting
  2023-504141-31-00 Phase II 1 country Institut fuer Klinische Krebsforschung IKF GmbH
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting
  2022-502046-28-00 Phase III 7 countries F. Hoffmann-La Roche AG
• Insemination in patients with polycystic ovary syndrome: gestation rates using two stimulation patterns: letrozole vs gonadotropins. Recruiting
  2023-503477-38-00 Phase III 1 country Hospital Universitario La Paz
• Mifepristone and Letrozole in Ectopic Pregnancy (MILE) Recruiting
  2023-503935-16-00 Phase II 1 country Karolinska Institutet
• ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer Recruiting
  2023-503533-21-00 Phase II 3 countries UZ Leuven
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
• MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer Recruiting
  2024-511219-78-00 Phase III 2 countries Swiss GO Trial Group
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 Phase II 1 country The Royal Marsden NHS Foundation Trust
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting
  2022-500764-35-00 Phase IV 1 country Institut Für Frauengesundheit GmbH
• ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz… Recruiting
  2023-508094-88-00 Phase III 1 country University Of Florence
• Trial that evaluates the interest of interruption versus maintaining the treatment of aromatase inhibitors in patients with metastatic low g… Recruiting
  2024-512629-97-00 Phase II 1 country Centre Leon Berard
• A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) Recruiting
  2023-503629-20-00 Phase I/II 3 countries F. Hoffmann-La Roche AG
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended
  2023-508827-10-00 Phase II 2 countries Solti Group
• A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Ended
  2024-518811-20-00 Phase II 2 countries F. Hoffmann-La Roche AG
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended
  2022-503001-38-01 Phase III 2 countries Novartis Pharma AG
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended
  2024-512925-95-00 Phase III 16 countries Pfizer Inc.
• A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II… Ended
  2024-516530-36-00 Phase III 1 country Cancer Trials Ireland
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended
  2024-513540-29-00 Phase III 5 countries Alliance Foundation Trials LLC
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended
  2022-501024-20-00 Phase III 14 countries Astrazeneca AB
• PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR A… Ended
  2024-515492-34-00 Phase I/II 1 country Pfizer Inc.

Showing 25–48 of 74 trials